FDA OK's Orexo’s Zubsolv to fight opioid dependence; shares up
This article was originally published in Scrip
Executive Summary
Just days after officials at the Center for Disease Control and Prevention (CDC) revealed a stunning report showing the deaths of women from overdoses of prescription opioids had jumped 415% in the past decade, the FDA has provided a new option in the battle against dependence on those medicines – approving Orexo's sublingual tablet Zubsolv (buprenorphine/naloxone).